Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
United BioPharma
With
Tri-Service General Hospital (TSGH)
This is an open-label, two-part, dose-escalation and comparative pharmacokinetics study of UB-921 in healthy male volunteers. There will be two parts: dose escalation study (Main Study) and comparative pharmacokinetics study (Sub-study).
Age
20–55
Sex
MALE
Healthy volunteers
Accepted
You may be eligible if
Total body weight ≧50 kg (110 lbs)
No clinically relevant abnormalities
To agree on using birth control barrier (eg. male condom) during the entire study period.
Signing the written informed consent form
You may not be if
Previous exposure to chimeric, humanized or human monoclonal antibody, whether licensed or investigational
A history of drug abuse or heavy drinking.
Blood donation over 250 mL within 90 days prior to the screening
Not in the condition to participate in this study considered by investigator(s)
Clareo Health | A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers
